Previous 10 | Next 10 |
- Application Assigned a PDUFA Date of May 27, 2021 - Dehydrated Alcohol Injection Market Estimated to be Greater Than $100 Million Annually - Application has Received Orphan Drug Designation for Methanol Poisoning DEER PARK, Ill., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Eton Pharma...
Eton Pharmaceuticals (ETON) has submitted a marketing application to the FDA seeking approval of topiramate oral solution for three indications:Monotherapy for partial-onset or primary general tonic-clonic seizures in patients at least two years old.Adjunctive therapy for partial-onset seizur...
- Application Submitted for the Treatment of Partial-Onset Seizures and Migraine - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Topiramate - Topiramate Oral Solution is Eton’s Third Neurology Product Candidate Submitted t...
CTI BioPharma (CTIC) +130% as company to file US application for pacritinib for thrombocytopenia.Yunji (YJ) +28% after company reported RMB87.5M in GMV and 10.7M views during its live streaming show.Jiayin Group (JFIN) +18% on acquisition of 35% equity interest i...
The FDA has approved Eton Pharmaceuticals' (ETON) ALKINDI SPRINKLE (hydrocortisone) oral granules as replacement therapy for Adrenocortical Insufficiency ((AI)) in children under 17 years of age.Pediatric AI is a rare disease characterized by an inability to synthesize and release cortis...
-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children -Eton expects ALKINDI SPRINKLE to be available in the fourth quarter of 2020 DEER PARK, Ill., Sept. 29, 2020 (GLOBE NEWSWIRE...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadA relatively light earnings and conference calendar in the week ahead doesn't mean a break for investors. The U.S. airlin...
Bausch Health Companies (BHC) and Eton Pharmaceuticals (ETON) announces that FDA approves Alaway Preservative Free ophthalmic solution antihistamine eye drops as the first OTC preservative-free formulation eye drop."We expect Alaway Preservative Free will be available for purchase i...
FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035% First OTC Preservative-Free Eye Drop Approved for the Treatment of Itchy Eyes Associated with Allergies Provides Up to 12 Hours of Eye Itch Relief PR Newswire L...
Nikola Corporation (NKLA) -26% after Milton resignation sends shockwaves.Eastman Kodak (KODK) -11%.Uranium Energy (UEC) -9%.Eton Pharmaceuticals (ETON) -7%.Deutsche Bank Aktiengesellschaft (DB) -7% on money laundering allegations.ING Groep N.V. (ING) -7%.Plug Power (PLUG) ...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...